ORLEANS, ON, June 14, 2019 /CNW/ - Tetra Bio-Pharma
Inc. ("Tetra" or the "Corporation") (TSXV:
TBP) (OTCQB: TBPMF), a global leader in cannabinoid-based drug
development and discovery, wishes to announce that Mr. Benoit Chotard has tendered his resignation as
director of the Corporation, effective immediately, in order to
devote time to manage his other professional commitments.
Furthermore, Mr. Chotard has advised the Corporation that he will
not stand for re-election to the board of directors of the
Corporation. The Corporation hereby wishes to withdraw his
nomination for election as a director at the upcoming annual
general meeting of shareholders scheduled to be held on
June 20, 2019 (the
"Meeting").
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a
biopharmaceutical multifaced corporation with its primary focus in
cannabinoid-based drug discovery and development with a clinical
trial program aimed at bringing novel drugs and treatments to
patients and their healthcare providers. Tetra Bio-Pharma's
subsidiary, Tetra Natural Health, also focuses on the development
and commercialization of natural health and self-care products as
well as the sale of its hemp energy drinks.
For more information visit: www.tetrabiopharma.com and
www.tetranaturalhealth.com
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-looking statements
Some statements in this
release may contain forward-looking information. All statements,
other than of historical fact, that address activities, events or
developments that the Company believes, expects or anticipates will
or may occur in the future (including, without limitation,
statements regarding potential acquisitions and financings) are
forward-looking statements. Forward-looking statements are
generally identifiable by use of the words "may", "will", "should",
"continue", "expect", "anticipate", "estimate", "believe",
"intend", "plan" or "project" or the negative of these words or
other variations on these words or comparable terminology.
Forward-looking statements are subject to a number of risks and
uncertainties, many of which are beyond the Company's ability to
control or predict, that may cause the actual results of the
Company to differ materially from those discussed in the
forward-looking statements. Factors that could cause actual results
or events to differ materially from current expectations include,
among other things, without limitation, the inability of the
Company to obtain sufficient financing to execute the Company's
business plan; competition; regulation and anticipated and
unanticipated costs and delays, the success of the Company's
research and development strategies, including the success of CAUMZ
and its other drug candidates, the applicability of the discoveries
made therein, the successful and timely completion and
uncertainties related to the regulatory process including the
applications for Orphan Drug Designation, the timing of clinical
trials, the timing and outcomes of regulatory or intellectual
property decisions and other risks disclosed in the Company's
public disclosure record on file with the relevant securities
regulatory authorities. Although the Company has attempted to
identify important factors that could cause actual results or
events to differ materially from those described in forward-looking
statements, there may be other factors that cause results or events
not to be as anticipated, estimated or intended. Readers should not
place undue reliance on forward-looking statements. The
forward-looking statements included in this news release are made
as of the date of this news release and the Company does not
undertake an obligation to publicly update such forward-looking
statements to reflect new information, subsequent events or
otherwise unless required by applicable securities
legislation.
SOURCE Tetra Bio-Pharma Inc